Document:

ex_143281.htm

Exhibit 10.2

 

SECOND AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE ISSUED ON SEPTEMBER 17, 2018

 

THIS SECOND AMENDMENT TO THE CONVERTIBLE PROMISSORY NOTE ISSUED ON September 17, 2018 (the “Amendment”) is made effective as of May 3, 2019 (the “Effective Date”), by and between NUO THERAPUETICS, INC., a Delaware corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Holder”) (each the Company and the Holder a “Party” and collectively the “Parties”).

 

BACKGROUND

 

	 	
			A.

				
			WHEREAS, The Company and Holder are the parties to that certain securities purchase agreement (the “SPA”) dated September 17, 2018 pursuant to which the Company issued to Holder a convertible note on even date, in the original principal amount of $175,000.00 (the “Note”); and

			

 

	 	
			B.

				
			WHEREAS, in accordance with the terms of Section 1.8 of the Note, as previously amended, the Company may prepay the Note until April 30, 2019 (the “Prepayment Termination Date”), with no prepayment permitted thereafter; and

			

 

	 	
			C.

				
			WHEREAS, the Parties desire to amend the Note as set forth expressly below.

			

 

NOW THEREFORE, in consideration of the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1.     As of the Effective Date of this Amendment if: (i) no Event of Default (as defined under the Note) shall have occurred; (ii) there is no breach of any of the terms of this Amendment; (iii) the Company wires the amount of $8,500.00 to the Holder in accordance with the wire transfer instructions attached hereto as Exhibit A no later than end of business day May 3, 2019 (“Payment Deadline”) (which will not reduce the balance owed under the Note); then: (a) the Prepayment Termination Date shall be May 31, 2019, provided that any prepayment of the Note prior to or on this new Prepayment Termination Date shall be subject to the last applicable Prepayment Factor (which is 145% of the outstanding balance of the Note) as set forth in the Note; and (b) the Holder shall refrain from exercising its right to convert the Note until May 31, 2019, provided however, in the event that the Company and all other holders of convertible debt do not as of the date hereof also agree in a signed writing in the same form and substance as the terms contained in this Amendment, specifically, agreeing to extend the period that Company is permitted to prepay its other convertible notes by at least an additional 31 days, and/or the other noteholders fail to agree in a signed writing to refrain from exercising their conversion rights under their respective outstanding convertible notes by at least an additional 31 days then this Amendment shall be null and void.

 

2.     Upon the: (i) occurrence of an Event of Default (as defined in the Note), or (ii) Company’s breach of any provision or representation in this Amendment this Amendment shall be null and void and the Holder shall automatically, immediately and without further action be entitled to all its rights, privileges, and preferences under the Note.

 

3.     This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the Note. Except as specifically modified hereby, all of the provisions of the Note, which are not in conflict with the terms of this Amendment, shall remain in full force and effect.

 

4.     This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. Any signature transmitted by facsimile, e-mail, or other electronic means shall be deemed to be an original signature.

 

 

[Signature page to follow]

 

1

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

	
			Nuo Therapeutics

			 

			By: /s/ David Jorden

			Name: David E. Jorden

			Title: CEO

				
			EMA Financial, LLC

			 

			By: /s/ Felicia Preston

			Name: Felicia Preston

			Title: Director

			

 

2Exhibit

EXECUTION

FOURTEENTH SUPPLEMENTAL INDENTURE
FOURTEENTH SUPPLEMENTAL INDENTURE (this “Fourteenth Supplemental Indenture”) dated as of March 12, 2019 among LIFESHIELD, LLC, a Delaware limited liability company, and LIFESHIELD SECURITY LLC, a Delaware limited liability company (each a “New Guarantor” and, collectively, the “New Guarantors”), each a subsidiary of PRIME SECURITY SERVICES BORROWER, LLC (or its successor), a Delaware limited liability company, and THE ADT SECURITY CORPORATION (or its successor), a Delaware corporation (the “Company”), and WELLS FARGO BANK NATIONAL ASSOCIATION, a national banking association, as trustee under the indenture referred to below (the “Trustee”).
W I T N E S S E T H :
WHEREAS, the Company and the Trustee executed and delivered an Indenture, dated as of July 5, 2012 (as originally executed or as it may be from time to time supplemented or amended by one or more supplemental indentures supplemental thereto, the “Indenture”), to provide for the issuance by the Company from time to time of unsubordinated debt securities evidencing its unsecured indebtedness; 
WHEREAS, the Company has issued (i) $1,000,000,000 of 3.500% Notes due 2022 (the “2022 Notes”), (ii) $750,000,000 of 4.875% Notes due 2042 (the “2042 Notes”), (iii) $700,000,000 of 4.125% Senior Notes due 2023 (the “2023 Notes”) and (iv) $1,000,000,000 of 6.250% Senior Notes due 2021 (the “2021 Notes” and, together with the 2022 Notes, the 2042 Notes and the 2023 Notes, the “Secured Notes”);
WHEREAS, the Company, the Trustee and the existing Notes Guarantors have executed and delivered a Sixth Supplemental Indenture, dated as of April 8, 2016 (the “Sixth Supplemental Indenture”), to provide guarantees and security in respect of the 2022 Notes, the 2042 Notes and the 2023 Notes; 
WHEREAS, the Company, the Trustee and the existing Notes Guarantors have executed and delivered a Seventh Supplemental Indenture, dated as of April 22, 2016 (the “Seventh Supplemental Indenture”), to provide guarantees and security in respect of the 2021 Notes; and
WHEREAS, pursuant to the Indenture, the Sixth Supplemental Indenture and the Seventh Supplemental Indenture, the Trustee and the Company are authorized to execute and deliver this Fourteenth Supplemental Indenture;
NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the New Guarantors, the Company and the Trustee mutually covenant and agree for the equal and ratable benefit of the holders of the Secured Notes as follows:
1.    Defined Terms.  As used in this Fourteenth Supplemental Indenture, terms defined in the Indenture or in the preamble or recital hereto are used herein as therein defined.  The words “herein,” “hereof” and “hereby” and other words of similar import used in this Fourteenth 

Doc#: US1:12612719v3

Supplemental Indenture refer to this Fourteenth Supplemental Indenture as a whole and not to any particular section hereof.
2.    Agreement to Guarantee.  The New Guarantors hereby agree, jointly and severally with all existing Notes Guarantors, to guarantee the Company’s Obligations under the Secured Notes and the Indenture on the terms and subject to the conditions set forth in Article II of the Sixth Supplemental Indenture and Article II of the Seventh Supplemental Indenture, as applicable, and to be bound by all other applicable provisions of the Indenture, the Sixth Supplemental Indenture, the Seventh Supplemental Indenture and the Secured Notes and to perform all of the obligations and agreements of a guarantor under the Indenture, the Sixth Supplemental Indenture and the Seventh Supplemental Indenture, as applicable.
3.    Notices.  All notices or other communications to the New Guarantors shall be given as provided in Section 13.03 of the Indenture.
4.    Ratification of Indenture; Supplemental Indentures Part of Indenture.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Fourteenth Supplemental Indenture shall form a part of the Indenture for all purposes, and every holder of Secured Notes heretofore or hereafter authenticated and delivered shall be bound hereby.
5.    Governing Law.  THIS FOURTEENTH SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.
6.    Foreign Account Tax Compliance Act.  For purposes of compliance with the Foreign Account Tax Compliance Act, this Fourteenth Supplemental Indenture shall not result in a material modification of the Secured Notes.
7.    Trustee Makes No Representation.  The Trustee makes no representation as to the validity or sufficiency of this Fourteenth Supplemental Indenture.
8.    Counterparts.  The parties may sign any number of copies of this Fourteenth Supplemental Indenture.  Each signed copy shall be an original, but all of them together represent the same agreement.
9.    Effect of Headings.  The Section headings herein are for convenience only and shall not affect the construction thereof.

Doc#: US1:12612719v3

IN WITNESS WHEREOF, the parties hereto have caused this Fourteenth Supplemental Indenture to be duly executed as of the date first above written.

	
						
	 
	 
	 
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee

	 
	 
	 
	 
	 
	 

	 
	 
	 
	By:
	  /s/ Alexander Pabon

	 
	 
	 
	 
	Name: Alexander Pabon
	 

	 
	 
	 
	 
	Title: Assistant Vice President

[Signature Page to Fourteenth Supplemental Indenture]

IN WITNESS WHEREOF, the parties hereto have caused this Fourteenth Supplemental Indenture to be duly executed as of the date first above written.

	
						
	 
	 
	 
	LIFESHIELD, LLC

	 
	 
	 
	 
	 
	 

	 
	 
	 
	By:
	  /s/ Jeffrey Likosar

	 
	 
	 
	 
	Name: Jeffrey Likosar
	 

	 
	 
	 
	 
	Title: Executive Vice President and 
Chief Financial Officer

	
						
	 
	 
	 
	LIFESHIELD SECURITY LLC

	 
	 
	 
	 
	 
	 

	 
	 
	 
	By:
	  /s/ Jeffrey Likosar

	 
	 
	 
	 
	Name: Jeffrey Likosar
	 

	 
	 
	 
	 
	Title: Executive Vice President and 
Chief Financial Officer

	
						
	 
	 
	 
	THE ADT SECURITY CORPORATION

	 
	 
	 
	 
	 
	 

	 
	 
	 
	By:
	  /s/ Jeffrey Likosar

	 
	 
	 
	 
	Name: Jeffrey Likosar
	 

	 
	 
	 
	 
	Title: Executive Vice President and 
Chief Financial Officer

[Signature Page to Fourteenth Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]